TIAA CREF Investment Management LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,544,831 shares of the life sciences company’s stock after purchasing an additional 44,816 shares during the period. TIAA CREF Investment Management LLC owned 1.06% of Illumina worth $337,530,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Gravity Companies Inc. bought a new stake in Illumina in the fourth quarter valued at approximately $106,000. Dupont Capital Management Corp bought a new stake in Illumina in the third quarter valued at approximately $153,000. SeaCrest Wealth Management LLC bought a new stake in Illumina in the fourth quarter valued at approximately $154,000. Captrust Financial Advisors bought a new stake in Illumina in the fourth quarter valued at approximately $165,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Illumina by 113.9% in the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after buying an additional 410 shares during the period. 91.51% of the stock is owned by hedge funds and other institutional investors.
Several analysts have issued reports on ILMN shares. Wells Fargo & Co restated a “positive” rating and issued a $260.00 price objective (up previously from $250.00) on shares of Illumina in a research note on Tuesday, January 9th. BTIG Research assumed coverage on Illumina in a research note on Friday, January 5th. They set a “neutral” rating on the stock. Piper Jaffray Companies increased their target price on Illumina to $274.00 and gave the stock an “overweight” rating in a research note on Thursday, January 4th. Evercore ISI assumed coverage on Illumina in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 target price on the stock. Finally, BidaskClub upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. Illumina currently has an average rating of “Buy” and a consensus price target of $241.39.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $253.54 on Wednesday. The stock has a market capitalization of $37,270.00, a P/E ratio of 42.68, a P/E/G ratio of 3.35 and a beta of 0.93. Illumina, Inc. has a 12-month low of $158.02 and a 12-month high of $256.05. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to the consensus estimate of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.85 earnings per share. analysts forecast that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.